Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran; Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arch Med Res. 2021 Nov;52(8):777-787. doi: 10.1016/j.arcmed.2021.05.007. Epub 2021 Jun 5.
The ongoing outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as the latest threat to global health, causes overwhelming effects for the public healthcare systems worldwide. Of note, in addition to the respiratory complications, some patients with coronavirus disease 2019 (COVID-19) also develop serious cardiovascular injuries. Vasoactive peptides play an important role in a wide range of physiological and pathological conditions.
With the urgent need for exploring the specific therapeutic targets and biomarkers for the emerging COVID-19, the general aim of this review is to discuss the potentials of the vasoactive peptides including Angiotensin II (Ang II), vasoactive intestinal peptide (VIP), endothelin-1 (ET-1), calcitonin gene-related peptide (CGRP), natriuretic peptides, substance P (SP) and bradykinin (BK) as therapeutic targets and/or prognostic indicators for the COVID-19 pandemic.
Based on various observations some authors conclude that the assessment of vasoactive peptides shall be considered a routine part of COVID-19 patient monitoring, and they can serve as potential therapeutic targets for the disease management.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的持续爆发是对全球健康的最新威胁，对全球公共卫生系统造成了巨大影响。值得注意的是，除了呼吸系统并发症外，一些新型冠状病毒病 2019（COVID-19）患者还会出现严重的心血管损伤。血管活性肽在广泛的生理和病理条件下发挥着重要作用。
鉴于迫切需要探索新兴 COVID-19 的特定治疗靶点和生物标志物，本综述的总体目的是讨论血管活性肽（包括血管紧张素 II（Ang II）、血管活性肠肽（VIP）、内皮素-1（ET-1）、降钙素基因相关肽（CGRP）、利钠肽、P 物质（SP）和缓激肽（BK））作为 COVID-19 大流行的治疗靶点和/或预后标志物的潜力。
基于各种观察结果，一些作者得出结论，应将血管活性肽的评估视为 COVID-19 患者监测的常规部分，并且它们可以作为该疾病管理的潜在治疗靶点。
Zotero 插件
